129 related articles for article (PubMed ID: 37898840)
1. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
[TBL] [Abstract][Full Text] [Related]
2. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
[TBL] [Abstract][Full Text] [Related]
3. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
[TBL] [Abstract][Full Text] [Related]
4. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
[TBL] [Abstract][Full Text] [Related]
5. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
[TBL] [Abstract][Full Text] [Related]
6. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
[TBL] [Abstract][Full Text] [Related]
7. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse.
Lu CY; Uen YH; Tsai HL; Chuang SC; Hou MF; Wu DC; Juo SH; Lin SR; Wang JY
Br J Cancer; 2011 Mar; 104(7):1178-84. PubMed ID: 21343933
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.
Slade MJ; Payne R; Riethdorf S; Ward B; Zaidi SA; Stebbing J; Palmieri C; Sinnett HD; Kulinskaya E; Pitfield T; McCormack RT; Pantel K; Coombes RC
Br J Cancer; 2009 Jan; 100(1):160-6. PubMed ID: 19034279
[TBL] [Abstract][Full Text] [Related]
10. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
[TBL] [Abstract][Full Text] [Related]
11. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
[TBL] [Abstract][Full Text] [Related]
12. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
13. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.
Lu CY; Tsai HL; Uen YH; Hu HM; Chen CW; Cheng TL; Lin SR; Wang JY
Br J Cancer; 2013 Mar; 108(4):791-7. PubMed ID: 23422758
[TBL] [Abstract][Full Text] [Related]
15. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
16. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.
Murray NP; Reyes E; Salazar A; Lopez MA; Orrego S; Guzman E
Turk J Urol; 2020 May; 46(3):186-195. PubMed ID: 32401703
[TBL] [Abstract][Full Text] [Related]
17. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
[TBL] [Abstract][Full Text] [Related]
19. Secondary Circulating Tumor Cells (CTCs) but not Primary CTCs are Associated with the Clinico-Pathological Parameters in Chilean Patients With Colo-Rectal Cancer.
Murray NP; Albarran V; Perez G; Villalon R; Ruiz A
Asian Pac J Cancer Prev; 2015; 16(11):4745-9. PubMed ID: 26107235
[TBL] [Abstract][Full Text] [Related]
20. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
